Related Experiment Video
Updated: Apr 26, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
Recent advances in pharmacotherapy for hypertriglyceridemia
Amirhossein Sahebkar1, Gerard T Chew2, Gerald F Watts3
1Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
Progress in Lipid Research
|August 2, 2014
Summary
New triglyceride-lowering therapies show promise for cardiovascular disease risk, hepatic steatosis, and pancreatitis. While some agents reduce triglyceride levels, their impact on cardiovascular events requires further investigation.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Metabolic Diseases
Background:
- Elevated plasma triglycerides (TG) increase risks for atherosclerotic cardiovascular disease (CVD), hepatic steatosis, and pancreatitis.
- Current therapies for hypertriglyceridemia offer partial efficacy.
- Novel agents targeting triglyceride-rich lipoprotein (TRL) metabolism are under development.
Purpose of the Study:
- To review the efficacy and safety of emerging TG-lowering therapies.
- To explore the potential of these agents in managing related metabolic conditions.
- To summarize clinical trial findings on novel hypertriglyceridemia treatments.
Main Methods:
- Review of clinical trial data for novel TG-lowering agents.
- Categorization of therapies based on their mechanism of action (e.g., TRL production inhibition, TRL catabolism enhancement).
- Analysis of reported TG reduction, safety profiles, and ongoing CVD outcome trials.
Main Results:
- Multiple novel agents target TRL metabolism through various pathways, including PPAR agonism, enzyme inhibition (MTTP, DGAT-1), and modulation of ANGPTLs and PCSK9.
- Some therapies demonstrate significant TG reduction, while others show inconsistent results.
- Ongoing trials are evaluating the impact of CETP inhibitors and PCSK9 monoclonal antibodies on CVD outcomes.
Conclusions:
- Novel therapies offer diverse mechanisms to lower plasma TG.
- Further research is needed to establish the cardiovascular benefits and broader metabolic applications of these agents.
- Efficacy and safety data are still emerging for many new TG-lowering treatments.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:26Atherosclerosis III: Management
719
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
719
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
611
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
611
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K